You are here

Multicenter Phase II Study of Transanal Total Mesorectal Excision (taTME) with Laparoscopic Assistance for Rectal Cancer

Multicenter Phase II Study of Transanal Total Mesorectal Excision (taTME) with Laparoscopic Assistance for Rectal Cancer | ASCRS

Transanal Total Mesorectal Excision (taTME) is a novel minimally invasive surgical approach for the treatment of rectal cancer. With the taTME approach, much of the rectal dissection is completed transanally through specialized endoscopic platforms, which overcomes many of the challenges related to deep pelvic dissection.

Since the first taTME clinical report in 2009, the approach has been increasingly adopted worldwide. While preliminary outcomes of taTME are encouraging, they are limited to case series and one international registry.

The US Multicenter Study of taTME for rectal cancer opened for enrollment in May 2017 (clinicaltrials.gov NCT03144765). This is a 5-year Phase II clinical trial investigating taTME with laparoscopic or robotic assistance in patients with resectable rectal cancer and who are eligible for sphincter preservation. The trial will enroll a total of 100 patients over 11 US study sites. It is anticipated that this trial will help validate the safety and efficacy of taTME with regards to three outcomes: quality of the resection achieved, perioperative outcomes, and oncologic and functional outcomes.

The trial is led by Patricia Sylla, MD at Mount Sinai Hospital and is funded in part by a generous grant from the Research Foundation of the American Society of Colon and Rectal Surgeons (RF ASCRS). The trial is also sponsored by the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) through grant support from Applied Medical, Conmed, Ethicon, Intuitive, Karl Storz, Medtronic, Novadaq, Olympus, Richard Wolf, and Stryker.

For more information regarding the trial, please visit clinicaltrials.gov

To register for the taTME course at the ASCRS Annual Scientific Meeting visit the course registration page.